Outcomes of pregnancy in women with hypertrophic cardiomyopathy: A systematic review

Moolla, Muhammad; Mathew, Anoop; John, Kevin D.; Yogasundaram, Haran; Alhumaid, Waleed; Campbell, Sandra; Windram, Jonathan

doi:10.1016/j.ijcard.2022.04.034

Cited by 9 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of experiencing an adverse cardiac event is proportional to the degree of symptoms and/or the degree of LVOT obstruction prior to pregnancy. Limited retrospective and observational data have shown that the incidence of maternal death in individuals with HCM was low at 0.2%, with a similarly low occurrence of neonatal death (0.2%) [ 20 ]. Family planning and pre-pregnancy counseling are especially important for women with HCM, as 40–60% of individuals have an identifiable genetic etiology of disease that is largely inherited in an autosomal dominant pattern.…”

Section: Heart Failure In Pregnancymentioning

confidence: 99%

Contemporary Management of Cardiomyopathy and Heart Failure in Pregnancy

Afari,

Sheehan,

Reza

2024

Cardiol Ther

View full text Add to dashboard Cite

Cardiovascular disease is the primary cause of pregnancy-related mortality and morbidity in the United States, and maternal mortality has increased over the last decade. Pregnancy and the postpartum period are associated with significant vascular, metabolic, and physiologic adaptations that can unmask new heart failure or exacerbate heart failure symptoms in women with known underlying cardiomyopathy. There are unique management considerations for heart failure in women throughout pregnancy, and it is imperative that clinicians caring for pregnant women understand these important principles. Early involvement of multidisciplinary cardio-obstetrics teams is key to optimizing maternal and fetal outcomes. In this review, we discuss the unique challenges and opportunities in the diagnosis of heart failure in pregnancy, management principles along the continuum of pregnancy, and the safety of heart failure therapies during and after pregnancy.

show abstract

Section: Heart Failure In Pregnancymentioning

confidence: 99%

Contemporary Management of Cardiomyopathy and Heart Failure in Pregnancy

Afari,

Sheehan,

Reza

2024

Cardiol Ther

View full text Add to dashboard Cite

show abstract

“…In the ROPAC registry, the rate of the composite endpoint of mortality and/or heart failure among cardiomyopathy patients was 28.3% and was highest in the dilated cardiomyopathy cohort compared with hypertrophic and other cardiomyopathy patients 5. Recently, a systematic review on pregnant patients with hypertrophic cardiomyopathy reported high frequency of non-fatal cardiovascular events but low rate of mortality (0.18%); still 10-fold higher than the general population in the USA 6. Since patients with cardiomyopathy can tolerate pregnancy in a heterogeneous manner, the subtype of cardiomyopathy is of major importance for the maternal outcome.…”

Section: Commentarymentioning

confidence: 99%

Cardiomyopathy and pregnancy: a high-risk combination

Ntiloudi

Giannakoulas

2023

Evid Based Nurs

View full text Add to dashboard Cite

“…Collectively, syncope occurred in 9% ( n = 26) of pregnancies, ventricular tachycardia (sustained and nonsustained) in 6% ( n = 54), HF in 5% ( n = 43), and atrial fibrillation in 4% ( n = 22). The incidence of maternal death was 0.2% [35 ▪▪ ]. Another recently published study examined outcomes for sixty pregnancies in forty-one patients with a prepregnancy history of HCM [36].…”

Section: Considerations For Specific Cardiomyopathies During Pregnancymentioning

confidence: 99%

Considerations for specific cardiomyopathies during pregnancy

Abrams

Magun

DeFilippis

2023

Current Opinion in Cardiology

View full text Add to dashboard Cite

Purpose of reviewMaternal mortality in the United States continues to increase. Cardiovascular disease, and in particular, cardiomyopathy and heart failure, serves as one of the principal causes of pregnancy-related mortality. The goal of this review is to summarize current knowledge on various cardiomyopathies in pregnancy, with an emphasis on cardiomyopathies beyond the most common in pregnancy, peripartum cardiomyopathy.Recent findingsAlthough existing literature is somewhat limited, outcome studies of cardiomyopathy in pregnancy have demonstrated increased risk for adverse cardiovascular events and maternal morbidity and mortality. Herein, we review and synthesize recent studies focusing on preconception risk and counseling, pharmacologic management, and maternal outcomes in various cardiomyopathies during pregnancy including: dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, noncompaction cardiomyopathy, and chemotherapy-induced cardiomyopathy.SummaryIn an effort to optimize maternal outcomes, it is critical to recognize the risk associated with various cardiomyopathies in pregnancy and understand the tools for risk stratification and antepartum management. Further research on less common cardiomyopathies in pregnancy is warranted to provide more standardized recommendations.

show abstract

Outcomes of pregnancy in women with hypertrophic cardiomyopathy: A systematic review

Cited by 9 publications

References 31 publications

Contemporary Management of Cardiomyopathy and Heart Failure in Pregnancy

Contemporary Management of Cardiomyopathy and Heart Failure in Pregnancy

Cardiomyopathy and pregnancy: a high-risk combination

Considerations for specific cardiomyopathies during pregnancy

Contact Info

Product

Resources

About